The administration of three doses of COVID-19 vaccine, της AstraZeneca, are effective against the rapidly spreading variant of the coronavirus, Omicron, the pharmaceutical company said on Thursday, citing data from a laboratory study University of Oxford.
The study’s findings, which have not yet been published in a medical journal, are consistent with those of rival pharmaceutical companies. Pfizer-BioNTech and Moderna, who have also found that a third dose of their vaccines works against Omicron.
The AstraZeneca vaccine study, Vaxzevria, showed that after administration of three doses of the vaccine, the neutralization levels against Omicron were generally similar to those against the variant Delta, of the virus, after two doses.
The company said the researchers at Oxford University, who conducted the study, were independent of those who worked on the AstraZeneca vaccine.
“As we better understand Omicron, we believe we will find that the T-cell response provides ongoing protection against serious disease and hospitalization.”, said Mr. Menelaos Pangalos, head of AstraZeneca’s biopharmaceutical R&D, referring to a critical component of the immune system that responds to the fight against infection.
The levels of anti-Omicron antibodies after the booster dose were higher than the antibodies in people who were infected and naturally recovered from COVID-19, the company official added.
The Oxford study analyzed blood samples from people who had been infected with COVID-19, those who had been vaccinated with two doses and a booster, and those who had previously been infected with other variants. It included samples from 41 subjects given three doses of Vaxzevria.
Dimitris G. Apokis